Correction of iodine deficiency in Macedonia.

A national survey conducted in 1995-96 showed that mild to moderate iodine deficiency existed in Macedonia (median urinary iodine [UI] concentration 117 microg/l). It was concluded that a new legal regulation should be introduced concerning the iodination of table salt for human consumption. The iodine level was recommended to be 20-30 mg/kg salt, exclusively in the form of the more stable potassium iodate. The new regulations were instituted and became effective in October, 1999. National surveys performed in 2000 and 2001 showed increased median UI concentrations (154.1 microg/l in 2000 and 164.5 microg/l in 2001). In 2001, UI excretion was assessed in 490 pregnant and lactating women (median UI concentration 140 microg/l). During the last three surveys, household salt specimens were assessed for iodine content. The findings showed an increase of the percentage of the optimal iodine content in household salt (42-69%), which correlated with the higher IU excretion results. The new regime of salt iodination was proved to be highly effective in correcting the iodine deficiency in Macedonia.

Reevaluation of the results of iodine prophylaxis in eradication of endemic goiter in Macedonia.

In order to reevaluate effectiveness of iodine prophylaxis in Macedonia, epidemiological, ultrasonographic studies and estimation of urine excretion were performed. The results from the epidemiological survey in nongoitrogenic regions demonstrated goiter between 12.8% and 18%. Much higher prevalence of goiter was found in goitrogenic regions, between 20.8% and 60.8%. The incidence of goiter increased with age, and its prevalence is higher in girls when compared with the boys of the same age group. The thyroid volume estimated by ultrasonography was higher in children from goitrogenic regions when compared to nongoitrogenic. There was a good correlation between ultrasonographic volumetry data and size of the thyroid estimated by palpation. Urinary iodine excretion demonstrated low values in children from goitrogenic regions as indicator of iodine deficiency.

Extended long-term drug monotherapy of Graves' disease.

The results are presented of a 3-17 years' prolongation of the usual one-year "long-term" drug treatment applied to patients with Graves' disease. Most of the 87 patients with an average age of 34.3 years were on the maintenance dose of 10 mg methimazole daily. This mono-drug therapy was well tolerated and accepted by the patients, the toxic state disappeared, glandular consistency and the size remained almost unchanged. Thirty-six patients of this group (41.4%) were in a "permanent" remission lasting over three years. The remaining 51 patients continued their maintenance dose which kept a balanced euthyroid state. The authors support the convenience of a considerable extension of the traditional long-term methimazole treatment of Graves' disease. This extended scheme of the drug suppression of euthyroid functions is reversible in contrast to radical surgical or radioiodine treatments which increase the cumulative rate of irreversible hypothyroidism over decades.